Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Amycretin

4 records for Amycretin, of which 1 are published trials.

Showing 0 records on this page

Records

4 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
REIMAGINE-1AmycretinPhase 1ReportedPhase 1 ascending dose1252024Low
REIMAGINE-1-RENAL-IMPprogramme recordAmycretinPhase 1ReportedPhase 1 ascending dose—2024Very low
REIMAGINE-1-PKprogramme recordAmycretinPhase 1ReportedPhase 1 ascending dose—2024Very low
REIMAGINE-1-DDIprogramme recordAmycretinPhase 1ReportedRandomised crossover—2024Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.